首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷

市場調查報告書

商品編碼

2126442

人工智慧病理學市場—策略分析與預測（2026-2035）

AI-Powered Pathology Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月12日 | 出版商:

Knowledge Sourcing Intelligence | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

人工智慧病理學市場預計將以 12.7% 的複合年成長率成長，從 2026 年的 2.0172 億美元成長到 2035 年的 5.8984 億美元。

全球人工智慧病理學市場正經歷變革性成長，這主要得益於癌症發生率的上升和病理檢查室數位化進程的加速。人工智慧病理學融合了機器學習、深度學習、電腦視覺和數位病理學技術，幫助病理學家檢測、分類、量化和解讀數位組織標本中的組織病理學觀察。該市場涵蓋軟體解決方案、配套硬體基礎設施和實施服務，旨在最佳化診斷工作流程，同時提高檢查室效率和診斷一致性。隨著癌症發生率的持續上升，對病理服務的需求不斷成長，而組織病理學評估仍然是診斷多種惡性腫瘤的黃金標準。醫療機構正在擴展其數位病理學能力，以應對日益成長的檢體量並減少機構間報告的差異。這些營運壓力推動了對人工智慧輔助診斷平台的需求，這些平台能夠自動執行重複性的影像分析任務，並優先處理具有臨床意義的觀察。該市場高度依賴全切片成像、計算病理學、雲端運算和標準化數位工作流程等方面的進步。這些基礎技術支援大規模影像擷取、安全資料儲存、演算法訓練和遠端會診，同時也使人工智慧模型能夠在現有檢查室基礎設施中運作。這些技術的整體成熟正推動人工智慧輔助病理學在日常臨床實踐中得到更廣泛的應用。

市場促進因素

臨床檢查室中數位病理學的擴展

數位病理學為人工智慧在常規診斷流程中的應用提供了必要的技術基礎。隨著集中式影像管理實現遠距會診、流程標準化和電腦輔助分析，醫院和診斷檢查室正日益將玻片數位化。這一轉變將使檢查室能夠存取規模大規模的數位資料集，供人工智慧演算法進行篩檢、定量分析和診斷決策支援。供應商正將人工智慧功能直接整合到其數位病理平台中，以降低部署複雜性並加速其在臨床環境中的應用。數位玻片庫與人工智慧輔助分析的結合，建構了一個擴充性的病理生態系統，支持檢查室的長期現代化。

癌症負擔日益加重，推動了對人工智慧輔助診斷技術的需求。

組織病理學檢查仍然是診斷大多數固態腫瘤的基礎，而病理處理能力直接取決於癌症發生率。儘管切片檢查數量的增加加重了診斷工作的負擔，但許多地區的醫療系統仍然面臨經驗豐富的病理學家短缺的問題。檢查室正在採用人工智慧驅動的影像分析技術，以優先識別可疑區域、自動進行生物標記定量分析並減少人工判讀時間，同時又不取代臨床監督。因此，技術開發人員正將產品開發重點放在腫瘤學應用領域，因為該領域臨床需求最高，且證據基礎最為充分。由此帶來的工作流程改進，既支持了精準腫瘤學項目，也提高了診斷的一致性。

監管方面的進步正在加速臨床人工智慧解決方案的商業化部署。

由於病理軟體直接影響診斷決策，其臨床應用取決於監管部門的批准。監管機構正在擴展醫療設備軟體（SaMD）的框架，鼓勵開發商進行嚴格的臨床檢驗並累積上市後證據。監管部門的核准能夠增強醫師的信心，擴大應用機會，促使製造商進一步增加對多中心檢驗試驗的投資。因此，與僅用於研究的解決方案相比，醫療服務提供者認為獲得監管部門批准的人工智慧應用風險較低。這種不斷變化的法規環境正在推動其在常規病理檢查室的商業化部署。

精準醫療正在推動對定量生物標記評估的需求。

在精準腫瘤學中，準確解讀生物標記對於指導標靶治療和免疫療法的選擇至關重要。人工生物標記評分常常導致觀察者間差異，尤其是在複雜的免疫組化評估中。醫療機構正在採用人工智慧驅動的定量分析來提高結果的可重複性，並支持標準化的治療決策。隨著製藥公司在臨床開發中對生物標記評估一致性的需求日益成長，科技公司正在擴展伴隨診斷工作流程的演算法。這些功能正在將人工智慧驅動的病理學確立為個人化醫療的關鍵組成部分。

市場限制因素

全切片成像系統、儲存基礎設備、軟體驗證和檢查室整合等相關高昂的部署成本，持續限制其在資源匱乏的醫療機構中的應用。監管合規要求、網路安全預期以及持續的演算法驗證，都增加了商業化的複雜性，並延長了產品開發週期。標準化、多樣化且帶有註釋的病理資料集的匱乏，也限制了演算法在不同人群、組織製備方法和檢查室環境中的通用性。

市場定義和範圍
病理行業概覽
人工智慧在病理學中的演變
主要市場趨勢
實際成果值市場規模分析
市場預測
數位病理生態系概述
將人工智慧引入整個病理工作流程
測試數量分析
已安裝的數位病理系統數量
用戶採納狀況分析
與臨床工作流程的整合
人工智慧驅動的診斷工作流程分析

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

新興技術
產品創新
臨床檢驗研究
人工智慧演算法發展的現狀
數位病理平台創新
管道分析
將人工智慧整合到整個實驗工作流程中
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求

第8章基於人工智慧的病理學市場：展望分析

分析：按技術
分析：依部署模式
分析：透過臨床應用
分析：按最終用戶
分析：按功能分類的人工智慧

第9章：人工智慧病理學市場：細分市場分析

透過技術
- 機器學習
- 深度學習
- 電腦視覺
- 自然語言處理
- 人工智慧世代
- 其他
按組件
- 軟體
- 硬體
- 服務
按部署模式
- 基於雲端的
- 現場
臨床應用
- 瘤
- 胃腸病理學
- 泌尿生殖系統病理學
- 皮膚病理學
- 血液病理學
- 呼吸病理學
- 其他臨床用途
最終用戶
- 醫院
- 獨立診斷檢查室
- 學術研究機構
- 其他

第10章基於人工智慧的病理學市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：人工智慧病理學市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
日本
中國
印度
韓國
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Visiopharm A/S
Tribun Health SAS
Lumea Inc.
Mindpeak GmbH
PathAI, Inc.
Paige AI, Inc.
Ibex Medical Analytics Ltd.
Aiforia Technologies Plc
Proscia Inc.

第14章：人工智慧病理學市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009160

The AI-Powered Pathology Market is forecast to grow at a CAGR of 12.7%, reaching USD 589.84 million in 2035 from USD 201.72 million in 2026.

The global AI-powered pathology market is experiencing transformative growth, driven by the rising incidence of cancer and the accelerating digitalization of pathology laboratories. AI-powered pathology combines machine learning, deep learning, computer vision, and digital pathology technologies to assist pathologists in detecting, classifying, quantifying, and interpreting histopathological findings from digitized tissue slides. The market includes software solutions, supporting hardware infrastructure, and implementation services that enhance diagnostic workflows while improving laboratory productivity and diagnostic consistency. Demand is increasing because cancer incidence continues creating sustained demand for pathology services, as histopathological evaluation remains the reference standard for diagnosing many malignancies. Healthcare providers are expanding digital pathology capabilities to accommodate increasing specimen volumes while reducing reporting variability across institutions. This operational pressure increases demand for AI-assisted diagnostic platforms capable of automating repetitive image analysis tasks and prioritizing clinically significant findings. The market depends heavily on advances in whole-slide imaging, computational pathology, cloud computing, and standardized digital workflows. These enabling technologies support large-scale image acquisition, secure data storage, algorithm training, and remote consultation while allowing AI models to operate within existing laboratory infrastructure. Their combined maturity is expanding the practical implementation of AI-assisted pathology across routine clinical practice.

Market Drivers

Increasing Digital Pathology Adoption Across Clinical Laboratories

Digital pathology provides the technological foundation required for artificial intelligence to operate within routine diagnostic workflows. Hospitals and diagnostic laboratories are increasingly digitizing glass slides because centralized image management enables remote consultations, workflow standardization, and computational analysis. This transition exposes laboratories to substantially larger digital datasets that AI algorithms can process for screening, quantification, and diagnostic decision support. Vendors are integrating AI capabilities directly into digital pathology platforms to reduce implementation complexity and strengthen clinical adoption. The combination of digital slide repositories and AI-assisted analysis establishes a scalable pathology ecosystem that supports long-term laboratory modernization.

Rising Oncology Burden Is Expanding Demand for AI-Assisted Diagnostic Support

Histopathological examination remains the diagnostic cornerstone for most solid tumors, making pathology capacity directly dependent on cancer incidence. Growing biopsy volumes are increasing diagnostic workloads while healthcare systems continue facing shortages of experienced pathologists in many regions. Laboratories are adopting AI-assisted image analysis to prioritize suspicious regions, automate biomarker quantification, and reduce manual interpretation time without replacing clinical oversight. Technology developers are therefore concentrating product development on oncology applications because these areas generate the highest clinical demand and strongest evidence base. The resulting workflow improvements strengthen diagnostic consistency while supporting precision oncology programs.

Regulatory Progress Is Accelerating Commercial Deployment of Clinical AI Solutions

Clinical adoption depends on regulatory confidence because pathology software directly influences diagnostic decision-making. Regulatory agencies are expanding frameworks for software as a medical device (SaMD), encouraging developers to generate robust clinical validation and post-market evidence. Manufacturers are investing more heavily in multicenter validation studies because regulatory clearance increases physician confidence and procurement opportunities. Healthcare providers consequently view regulatory-approved AI applications as lower-risk investments compared with research-only solutions. This regulatory evolution strengthens commercial deployment across routine pathology laboratories.

Precision Medicine Is Increasing Demand for Quantitative Biomarker Assessment

Precision oncology relies on accurate biomarker interpretation to guide targeted therapies and immunotherapy selection. Manual biomarker scoring often introduces inter-observer variability, particularly for complex immunohistochemistry assessments. Healthcare providers are implementing AI-assisted quantification to improve reproducibility and support standardized treatment decisions. Technology companies are expanding algorithms for companion diagnostic workflows because pharmaceutical developers increasingly require consistent biomarker evaluation during clinical development. These capabilities position AI-powered pathology as an important component of personalized medicine.

Market Restraints

High implementation costs associated with whole-slide imaging systems, storage infrastructure, software validation, and laboratory integration continue limiting adoption among resource-constrained healthcare providers. Regulatory compliance requirements, cybersecurity expectations, and continuous algorithm validation increase commercialization complexity while extending product development timelines. Limited availability of standardized, diverse, and annotated pathology datasets constrains algorithm generalizability across different populations, tissue preparation methods, and laboratory environments.

Technology and Segment Insights

By Component

Software represents the largest source of innovation because artificial intelligence algorithms, workflow orchestration platforms, image management systems, and decision-support applications generate the primary clinical value. Healthcare organizations are increasingly prioritizing enterprise software platforms that integrate seamlessly with laboratory information systems and whole-slide imaging infrastructure. This requirement increases demand for interoperable solutions capable of supporting routine diagnostics rather than isolated analytical tasks. Vendors are continuously enhancing algorithm performance, cloud deployment, cybersecurity, and workflow automation to improve scalability across large pathology networks.

By Clinical Application

Oncology constitutes the leading clinical application because histopathological evaluation remains essential for cancer diagnosis, grading, staging, biomarker assessment, and treatment planning. Cancer screening programs and precision medicine initiatives are continuously increasing tissue specimen volumes processed by pathology laboratories. Healthcare providers are adopting AI-assisted pathology to improve diagnostic consistency, automate biomarker quantification, and reduce reporting turnaround times. Technology developers are concentrating product pipelines on breast, prostate, lung, colorectal, and other common cancers because these indications present substantial clinical evidence and commercial opportunity.

By End User

Hospitals represent the largest end-user segment because comprehensive pathology laboratories support a broad range of surgical pathology, oncology, and multidisciplinary diagnostic services. Healthcare systems are expanding digital pathology infrastructure to improve laboratory productivity while facilitating collaboration across multiple clinical departments. AI-powered decision support increasingly assists hospital pathologists in prioritizing complex cases, standardizing interpretations, and managing rising diagnostic workloads. Independent diagnostic laboratories and academic and research institutes represent additional significant end-user segments.

Competitive and Strategic Outlook

The competitive landscape features specialized AI pathology companies and larger diagnostic organizations. F. Hoffmann-La Roche Ltd. remains strategically distinct because it combines global diagnostics leadership with an integrated digital pathology ecosystem supporting precision oncology and companion diagnostics. PathAI, Inc. differentiates itself through its strong focus on AI for pathology, translational medicine, and pharmaceutical research. Paige AI, Inc. distinguishes itself through clinically validated AI applications designed specifically for routine pathology diagnostics. Ibex Medical Analytics Ltd. differentiates itself through AI-powered diagnostic decision support for routine pathology workflows. Aiforia Technologies Plc establishes differentiation through a cloud-based AI platform supporting both clinical diagnostics and biomedical research. Proscia Inc. differentiates itself through an enterprise digital pathology platform combining workflow management, image management, and AI within a unified ecosystem.
Strategic developments include increasing integration of multimodal AI combining histopathology with genomic and clinical data, expansion of companion diagnostics, and growth of cloud-based pathology platforms. Companies are forming partnerships to strengthen algorithm validation, clinical adoption, and regulatory submissions. Technology expansions focus on enterprise software platforms, workflow automation, and biomarker quantification. Companies that successfully combine validated algorithms with scalable digital pathology ecosystems are expected to lead the market.

Conclusion

The AI-powered pathology market is poised for significant growth, driven by rising cancer diagnostic volumes, digital pathology adoption, and precision medicine. The evolution from algorithm-centric innovation toward enterprise-wide diagnostic transformation is reshaping pathology practice. Companies that successfully deliver clinically validated, interoperable, and scalable AI-powered pathology solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding digital health infrastructure will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. AI-Powered Pathology Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Pathology Industry Overview
3.3 Evolution of AI in Pathology
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Digital Pathology Ecosystem Overview
3.8 Adoption of AI Across Pathology Workflow
3.9 Testing Volume Analysis
3.10 Installed Base of Digital Pathology Systems
3.11 User Adoption Analysis
3.12 Clinical Workflow Integration
3.13 AI-Assisted Diagnostic Workflow Analysis

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies
6.2 Product Innovation
6.3 Clinical Validation Studies
6.4 AI Algorithm Development Landscape
6.5 Digital Pathology Platform Innovation
6.6 Pipeline Analysis
6.7 AI Integration Across Laboratory Workflows
6.8 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. AI-Powered Pathology Market Landscape Analysis

8.1 Analysis by Technology
8.2 Analysis by Deployment Model
8.3 Analysis by Clinical Application
8.4 Analysis by End User
8.6 Analysis by AI Functionality

9. AI-Powered Pathology Market Segment Analysis (2021-2035)

9.1 By Technology
- 9.1.1 Machine Learning
- 9.1.2 Deep Learning
- 9.1.3 Computer Vision
- 9.1.4 Natural Language Processing
- 9.1.5 Generative AI
- 9.1.6 Others
9.2 By Component
- 9.2.1 Software
- 9.2.2 Hardware
- 9.2.3 Services
9.3 By Deployment Model
- 9.3.1 Cloud-Based
- 9.3.2 On-Premises
9.4 By Clinical Application
- 9.4.1 Oncology
- 9.4.2 Gastrointestinal Pathology
- 9.4.3 Genitourinary Pathology
- 9.4.4 Dermatopathology
- 9.4.5 Hematopathology
- 9.4.6 Pulmonary Pathology
- 9.4.7 Other Clinical Applications
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Independent Diagnostic Laboratories
- 9.5.3 Academic & Research Institutes
- 9.5.4 Others

10. AI-Powered Pathology Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. AI-Powered Pathology Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Netherlands
11.9 Japan
11.10 China
11.11 India
11.12 South Korea
11.13 Australia
11.14 Brazil
11.15 Saudi Arabia

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Visiopharm A/S
13.3 Tribun Health SAS
13.4 Lumea Inc.
13.5 Mindpeak GmbH
13.6 PathAI, Inc.
13.7 Paige AI, Inc.
13.8 Ibex Medical Analytics Ltd.
13.9 Aiforia Technologies Plc
13.10 Proscia Inc.